Find a Doctor

Grant M. Mcarthur-Arthur

Peter Maccallum Cancer Centre
Male

Bio


Grant Mcarthur-Arthur is in Melbourne, Australia. They have been an author on 248 peer reviewed articles and participated in 1 clinical trial in the past 15 years.

Contact

Melbourne, VIC, AU

Latest Research


Latest Advance
Study
  • Condition: Metastatic Merkel Cell Carcinoma (mMCC)
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Immune Checkpoint Inhibitors (ICIs)
  • Number of Patients: 23
  • Published —
This study evaluated the effectiveness and safety of immune checkpoint inhibitors (stop the immune system from turning off before cancer is completely eliminated; ICIs) in patients with metastatic (has spread beyond the skin) Merkel cell carcinoma (rare and aggressive skin cancer; mMCC).
Latest Advance
Study
  • Condition: BRAF-mutated Metastatic Melanoma
  • Journal: Journal of translational medicine
  • Treatment Used: Dacarbazine or Vemurafenib?±?Cobimetinib
  • Number of Patients: 0
  • Published —
The study researched the safety and effectiveness of Dacarbazine or Vemurafenib?±?Cobimetinib for patients with BRAF-mutated metastatic melanoma.
Latest Advance
Study
  • Condition: BRAF-Mutant Melanoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Vemurafenib and Cobimetinib
  • Number of Patients: 63
  • Published —
This study reported on the long-term outcomes of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: The New England journal of medicine
  • Treatment Used: Combined Nivolumab and Ipilimumab
  • Number of Patients: 0
  • Published —
This study reported outcomes for nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.
Latest Advance
Study
  • Condition: BRAFV600-Mutated Metastatic Melanoma
  • Journal: British journal of cancer
  • Treatment Used: Vemurafenib or Cobimetinib plus Vemurafenib
  • Number of Patients: 0
  • Published —
This study investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.
Latest Advance
Study
  • Condition: Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Treated with Vemurafenib ± Cobimetinib
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Concomitant Dosing with Acid-Reducing Agents (ARAs) and Vemurafenib
  • Number of Patients: 920
  • Published —
This study evaluated the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the efficacy of vemurafenib in patients with BRAFV600 mutation-positive unresectable or metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.
Latest Advance
Study
  • Condition: Refractory solid tumors
  • Journal: Cancer chemotherapy and pharmacology
  • Treatment Used: Panobinostat
  • Number of Patients: 9
  • Published —
This study sought to describe dose limiting toxicities (DLT), pharmacokinetic (PK) profile, anti-tumor activity as well as biologic activity in pediatric patients taking panobinostat for refractory solid tumors.
Latest Advance
Study
  • Condition: Metastatic melanoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Vemurafenib
  • Number of Patients: 675
  • Published —
This study evaluated the effects of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma.

Clinical Trials


All Publications
View All


Publication
Study
  • Journal: Journal for immunotherapy of cancer
  • Published —
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.
Publication
Study
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Published —
Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.

Contact

Melbourne, VIC, AU

Insurance

Contact them to find out if they accept your insurance plan.